• by
    Pancreatic cancer can be a devastating disease. Fewer than 9% of patients with ductal adenocarcinoma of the pancreas are living 5 years after diagnosis. It is estimated that in 2019, about 57 000 people will be diagnosed with pancreatic cancer in the United States and that it may soon overtake colon cancer to become the second-most […]
  • by
    This qualitative study evaluates differences in design and implementation of rapid response teams at top-performing and non–top-performing sites for survival of in-hospital cardiac arrest.
  • by
    In Reply On behalf of my coauthors, I write to report errors in our article, “Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis,” that was published online in July 8, 2019, in JAMA Internal Medicine. In that article, we reported on a meta-analysis of 189 randomized clinical trials (RCTs) comprising 80 104 […]
  • by
    As the morbidity, mortality, and costs of diabetes grow nationwide, a new analysis by Kazemian and colleagues published in this issue of JAMA Internal Medicine shows that average-care goal achievement among adults with diabetes has remained stagnant over the past 12 to 15 years. Expanding on a previous report, this study used data from the […]
  • by
    This cross-sectional study uses Centers for Medicare & Medicaid Services data to evaluate the association between industry payments to physicians who prescribe gabapentinoids and gabapentinoid prescribing behavior.
  • by
    This cohort study evaluates the association of directly observed therapy with treatment adherencee in patients with apparent treatment-resistant hypertension.
  • by
    To the Editor We read the article by Smyth et al with interest. The authors performed a large meta-analysis to determine whether participants in large, multicenter dialysis trials were similar to the general population undergoing dialysis in terms of age, comorbidities, and mortality rate. They concluded that participants in large, multicenter randomized clinical trials of […]
  • by
    This population-based cohort study evaluates the risk of cardiac arrhythmia and other cardiovascular events in patients 66 years or older receiving the β3-adrenoceptor agonist mirabegron.
  • by
    In Reply We appreciate the comments by Hill and colleagues concerning the way we categorized naloxone access laws (NALs) in our article. We acknowledge the oversimplification issue in our investigation of the effect of NALs on opioid overdose deaths. The fact is that all NALs are different in some manner, whether it is by statute […]
  • by
    In Reply We would like to thank Medina and colleagues and Thompson Jr and colleagues for their interest and thoughtful comments on our article. We completely agree that the goal of observational studies is not to refute clinical trials, but rather to complement them through assessment of real-world practice. In the Prostate Cancer Prevention Trial, […]

Author Interviews